4th Quarter - Report
NCHC ACTION FUND for NCHC ACTION FUND
Firm
Client
Income
—
Expenses
$10,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Prescription drug pricing S. 974 - CREATES Act S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 2051 - FAST Generics Act of 2017 Medicare Part D biosimilars
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN ROTHER | — |
Medicare/Medicaid MMM
Prescription Drug Pricing Medicare Part D biosimilars
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN ROTHER | — |
Pharmacy PHA
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 2051 - FAST Generics Act of 2017 Medicare Part D biosimilars
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN ROTHER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.